Toutes les études
RecrutementPHASE2INTERVENTIONNEL

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

This research study is investigating a drug called inebilizumab for children and adolescents between 2 and 17 years old who have a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). These young people must also have specific antibodies in their blood called AQP4-IgG. The main goals of the study are to understand how the medicine moves through the body (pharmacokinetics), what effects it has on the body (pharmacodynamics), and how safe it is. Participants will receive the medicine intravenously over 28 weeks, and their health will be closely monitored throughout the study, which could last up to 80 weeks.

En un coup d'œil

Statut
Recrutement
Phase
PHASE2
Sponsor
Amgen
Objectif d'inscription
15
Démarrer
03 Jul 2023
Achèvement estimé
13 Apr 2027

De quoi parle cette étude ?

This study is focused on a rare condition called Neuromyelitis Optica Spectrum Disorder, or NMOSD. It's a condition where the body's immune system mistakenly attacks its own healthy cells, particularly in the brain and spinal cord, leading to a range of symptoms. This particular study is for children and teenagers aged between 2 and 17 years old who have been diagnosed with NMOSD and have a specific type of antibody in their blood.

The research aims to find out more about a new treatment called inebilizumab. It's important to understand how new medicines work in young people because their bodies can react differently compared to adults. The study will look at how the medicine is absorbed and used by the body, what effects it has, and how safe it is for this age group.

By carefully studying inebilizumab, researchers hope to gather important information that could help in the development of new and effective treatments for children and teenagers with NMOSD in the future. This kind of research is vital for improving the lives of those affected by rare conditions.

Points clés

  • This study is for children and teenagers with a specific type of NMOSD.
  • It's testing a new medicine called inebilizumab given intravenously.
  • The main goals are to check the medicine's safety and how it works in the body.
  • Participation involves regular clinic visits over a period of up to 80 weeks.
  • Your health will be closely monitored throughout the study.
  • Vous pouvez vous retirer de l'étude à tout moment.

Qui peut être éligible ?

To be considered for this study, participants must be between 2 and 17 years old, weigh at least 15 kg (about 2 stone 5 pounds), and have a clear diagnosis of NMOSD. They also need to have tested positive for specific antibodies (called AQP4-IgG) in their blood and have experienced at least one NMOSD relapse in the past year, or two or more relapses in the past two years.

There are also some reasons why someone might not be able to join. For example, if they have other significant health problems affecting their liver, kidneys, or blood, or if they are currently taking part in another drug study. Also, if they have recently received certain other treatments for NMOSD or similar conditions, they might not be eligible. The study team will review all your medical information carefully to see if this study is right for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous entre 2 et 17 ans ?
  2. Do you weigh at least 15 kg?
  3. Have you been diagnosed with Neuromyelitis Optica Spectrum Disorder?
  4. Have you had a positive blood test for AQP4-IgG antibodies?
  5. Have you experienced an NMOSD relapse in the last year, or two or more in the last two years?
  6. Are you currently free from other major health issues or recent specific treatments that might prevent your participation?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you would receive the study medicine, inebilizumab, directly into your vein (intravenously) over a period of 28 weeks. The study involves several visits to the clinic. First, there's a screening period of up to 4 weeks to check if you're suitable. Then, during the 28-week treatment period, you'll have about 9 visits. After that, there's a follow-up period of about 52 weeks, with approximately 4 visits to monitor your health. The total time you would be involved in the study could be up to 80 weeks (about a year and a half). Your health will be regularly checked throughout this time to ensure your safety and monitor the effects of the treatment.

Risques et avantages potentiels

Participating in a clinical trial could offer the potential benefit of accessing a new treatment for your condition that is not yet widely available. However, there are also potential risks involved, as with any new medicine. These could include side effects from the medication or discomfort from procedures like blood tests or infusions. Your safety will be closely monitored by the study team, and you will receive regular medical check-ups. You are completely free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Emplacements (19)

  • UCSD Altman Clinical and Translational Research Institute Building
    Code postal vérifié
    La Jolla, United States· Recrutement
  • Loma Linda University Children's Hospital - PIN
    Code postal vérifié
    Loma Linda, États-Unis· Recrutement
  • Hôpital Général du Massachusetts
    Code postal vérifié
    Boston, États-Unis· Recrutement
  • University of Texas Southwestern Medical Center
    Code postal vérifié
    Dallas, United States· Recrutement
  • Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan
    Code postal vérifié
    Parque Patricios, Argentina· Recrutement
  • Hospital Santa Izabel-Rua Floriano Peixoto 300
    Code postal vérifié
    Salvador, Brazil· Recrutement
  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
    Non vérifié
    Porto Alegre/RS, Brazil· Recrutement
  • CPQuali Pesquisa Clínica Sao Paulo
    Code postal vérifié
    São Paulo, Brésil· Recrutement
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    Code postal vérifié
    São Paulo, Brésil· Recrutement
  • Hospital For Sick Children
    Code postal vérifié
    Toronto, Canada· Recrutement
  • Centre Hospitalier Universitaire de Bicêtre
    Code postal vérifié
    Le Kremlin-Bicêtre, France· Recrutement
  • Erasmus MC Sophia Children's Hospital-Wytemaweg 80
    Code postal vérifié
    Rotterdam, Netherlands· Recrutement

Questions fréquentes

What is NMOSD?

NMOSD is a rare condition where your body's immune system mistakenly attacks healthy cells, mainly in the brain and spinal cord.

What is inebilizumab?

Inebilizumab is the medicine being investigated in this study. It's a potential new treatment for NMOSD that aims to help manage the condition.

Comment le médicament sera-t-il administré ?

The medicine will be given directly into a vein (intravenously), meaning through a drip.

Combien de temps vais-je participer à l'étude ?

If you join, the study participation could last for up to 80 weeks, which includes treatment and follow-up periods.

Puis-je quitter l'étude à tout moment ?

Yes, you have the right to withdraw from the study at any point, and it won't affect your ongoing medical care.

Comment en savoir plus

Amgen Call Center

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Study of Inebilizumab in Pediatric Subjects With Neuromyelit… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.